Research programme: cancer therapeutics - Ipsen

Drug Profile

Research programme: cancer therapeutics - Ipsen

Alternative Names: 17 beta hydroxysteroid dehydrogenase inhibitors - Ipsen; Cytotoxic-peptide conjugates - Ipsen; DASI - Ipsen; Dual aromatase-steroid sulfatase inhibitors - Ipsen; Prolactin receptor antagonists - Ipsen; SARD - Ipsen; Selective androgen receptor degraders - Ipsen; siRNA -peptide conjugates - Ipsen

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Class Antineoplastics; Peptides; Small interfering RNA
  • Mechanism of Action Androgen receptor degradation enhancers; Aromatase inhibitors; Estradiol dehydrogenase inhibitors; Prolactin receptor antagonists; RNA interference; Sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Oct 2016 Preclinical development is ongoing for Cancer in France (Ipsen pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France
  • 31 Dec 2010 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top